QUiPP App v.2预测模型的开发与验证:用于预测无症状高危女性早产的工具
本研究基于13家英国早产门诊的前瞻性数据,开发并验证了QUiPP App v.2预测模型,用于无症状高危女性自发性早产的风险预测。模型分别基于宫颈长度、定量胎儿纤维连接蛋白或两者联合,在<30、<34、<37周及检测后1、2、4周内的预测AUC为0.75-0.90(联合)、0.68-0.90(qfFN单独)、0.71-0.87(CL单独),三种算法间差异无统计学意义。校准显示4周内预测与观察率无显著差异,但22+0至25+6周CL测量存在轻微风险高估。
要点
- QUiPP App v.2基于CL、qfFN或两者联合预测无症状高危女性自发性早产,AUC达0.68-0.90。
- 联合CL与qfFN的AUC为0.75-0.90,单独qfFN为0.68-0.90,单独CL为0.71-0.87,三者差异无统计学意义。
- 校准显示4周内预测与观察率无显著差异,但22+0至25+6周CL测量存在轻微风险高估。
核心结论
- QUiPP App v.2是基于生物标志物、症状和统计算法组合的高精度自发性早产预测工具,可可靠用于向患者传达早产风险,并作为规划高危女性随访或住院的筛查工具;其在识别需预防性干预女性中的作用尚需进一步研究。
研究设计与样本
- 前瞻性二次分析,纳入13家英国早产门诊的无症状高危女性,训练集1803例(3878次就诊),验证集904例(1400次就诊);每2-4周行qfFN检测和/或经阴道超声CL测量(孕18+0至36+6周);采用生存分析筛选预测因子并构建模型,以ROC曲线AUC评估预测性能,并进行校准分析。
诊断标准与关键数值
- 联合qfFN与CL预测自发性早产的AUC为0.75-0.90,单独qfFN为0.68-0.90,单独CL为0.71-0.87,预测时间点为<30、<34、<37周及检测后1、2、4周内;三种算法间差异无统计学意义;校准显示4周内预测与观察率无显著差异,22+0至25+6周CL测量存在轻微风险高估。
临床应用与阅片要点
- 作者认为QUiPP App v.2可可靠用于向患者传达自发性早产风险,并作为规划高危女性随访或住院的筛查工具;作者指出其在识别需预防性干预女性中的作用尚需进一步研究。
局限性
- 原文指出其在识别需预防性干预女性中的作用尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Accurate mid-pregnancy prediction of spontaneous preterm birth (sPTB) is essential to ensure appropriate surveillance of high-risk women. Advancing the QUiPP App prototype, QUiPP App v.2 aimed to provide individualized risk of delivery based on cervical length (CL), quantitative fetal fibronectin (qfFN) or both tests combined, taking into account further risk factors, such as multiple pregnancy. Here we report development of the QUiPP App v.2 predictive models for use in asymptomatic high-risk women, and validation using a distinct dataset in order to confirm the accuracy and transportability of the QUiPP App, overall and within specific clinically relevant time frames.
METHODS: This was a prospective secondary analysis of data of asymptomatic women at high risk of sPTB recruited in 13 UK preterm birth clinics. Women were offered longitudinal qfFN testing every 2-4 weeks and/or transvaginal ultrasound CL measurement between 18 + 0 and 36 + 6 weeks' gestation. A total of 1803 women (3878 visits) were included in the training set and 904 women (1400 visits) in the validation set. Prediction models were created based on the training set for use in three groups: patients with risk factors for sPTB and CL measurement alone, with risk factors for sPTB and qfFN measurement alone, and those with risk factors for sPTB and both CL and qfFN measurements. Survival analysis was used to identify the significant predictors of sPTB, and parametric structures for survival models were compared and the best selected. The estimated overall probability of delivery before six clinically important time points (< 30, < 34 and < 37 weeks' gestation and within 1, 2 and 4 weeks after testing) was calculated for each woman and analyzed as a predictive test for the actual occurrence of each event. This allowed receiver-operating-characteristics curves to be plotted, and areas under the curve (AUC) to be calculated. Calibration was performed to measure the agreement between expected and observed outcomes.
RESULTS: All three algorithms demonstrated high accuracy for the prediction of sPTB at < 30, < 34 and < 37 weeks' gestation and within 1, 2 and 4 weeks of testing, with AUCs between 0.75 and 0.90 for the use of qfFN and CL combined, between 0.68 and 0.90 for qfFN alone, and between 0.71 and 0.87 for CL alone. The differences between the three algorithms were not statistically significant. Calibration confirmed no significant differences between expected and observed rates of sPTB within 4 weeks and a slight overestimation of risk with the use of CL measurement between 22 + 0 and 25 + 6 weeks' gestation.
CONCLUSIONS: The QUiPP App v.2 is a highly accurate prediction tool for sPTB that is based on a unique combination of biomarkers, symptoms and statistical algorithms. It can be used reliably in the context of communicating to patients the risk of sPTB. Whilst further work is required to determine its role in identifying women requiring prophylactic interventions, it is a reliable and convenient screening tool for planning follow-up or hospitalization for high-risk women. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Watson HA, Seed PT, Carter J, et al. Development and validation of predictive models for QUiPP App v.2: tool for predicting preterm birth in asymptomatic high-risk women. Ultrasound Obstet Gynecol. 2020. PMID: 31325332. doi:10.1002/uog.20401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。